title: Crunch time for heart failure care in England and Wales.
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002309:Cardiology; D002317:Cardiovascular Agents / Q000627:therapeutic use*; D004739:England / Q000453:epidemiology; D006333:Heart Failure / Q000175:diagnosis / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology / Q000401:mortality; D006801:Humans; D033183:Interdisciplinary Communication; D008485:Medical Audit; D000451:Mineralocorticoid Receptor Antagonists / Q000627:therapeutic use; D012017:Referral and Consultation; D012307:Risk Factors; D049994:Sodium Potassium Chloride Symporter Inhibitors / Q000627:therapeutic use; D013318:Stroke Volume; D006113:United Kingdom / Q000453:epidemiology; D014852:Wales / Q000453:epidemiology
chemical_list: D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D002317:Cardiovascular Agents; D000451:Mineralocorticoid Receptor Antagonists; D049994:Sodium Potassium Chloride Symporter Inhibitors